18 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
an innovative use of positron emission tomography (“PET”) scans and hypoxia-specific radiotracers to evaluate the oxygenating enhancing effects of TSC
8-K
EX-99.1
CRVO
CervoMed Inc
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
multiforme. The trial, which has been designated Study 200-208, has been designed to incorporate an innovative use of positron emission tomography
8-K
EX-99.1
enkhcgnmlq
27 Jul 22
Other Events
7:30am
S-3
EX-10.13
e7puxghwl3n58bn7h
15 Oct 99
Shelf registration
12:00am
S-3
EX-10.12
52oupqxiw 5tlpt
15 Oct 99
Shelf registration
12:00am
S-3
EX-10.14
lmomqx21y0eggl0f1ni
15 Oct 99
Shelf registration
12:00am
S-3
EX-10.15
4njd japn
15 Oct 99
Shelf registration
12:00am
- Prev
- 1
- Next